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Abstract
Canine mast cell tumours (MCTs) typically spread to lymph nodes (LNs) before reaching
distant sites, and LN assessment is an important part of MCT staging. Sentinel LN
(SLN) mapping techniques to identify draining LNs are being developed and could
improve the accuracy of MCT staging. The primary objective of this feasibility study
was to determine the safety and effectiveness of contrast-enhanced ultrasound (CEUS)
to identify SLNs. Secondary objectives were to determine if the SLNs identified by
CEUS coincided with the regional LN predicted by the anatomical lymphosomes, if pre-
vious MCT excision altered CEUS SLN findings, and if CEUS could identify MCT nodal
metastases. Between June 2017 and March 2019, 59 dogs with 62 MCTs were
enrolled. No adverse events related to CEUS were reported. CEUS detected at least
1 SLN in 59/62 MCTs (95.2%, 95% CI: 86.5-99.0%). In only 32/59 (54.2%) MCTs, clini-
cians would have correctly predicted the SLN(s) identified by CEUS. Among the
35 MCTs that had histological examination of the SLN(s), the prevalence of metastasis
was 60% (95% CI: 42.1-76.1%). Additional staging procedures did not reveal any
metastases in dogs with histologically non-metastatic SLNs. Integration of CEUS SLN
mapping into the routine staging of MCTs is promising, but future studies are required
to refine this procedure and to investigate if it would translate into a clinical benefit.
K E YWORD S
lymphosonography, mastocytosis, microbubble, sentinel lymph node
1 | INTRODUCTION
Regional lymph node (LN) assessment is an important part of staging
in canine mast cell tumours (MCTs), as they are generally considered
to be the first site of metastasis with this cancer.1,2 Step-wise staging
algorithms taking into account LN assessment have been
Abbreviations: CEUS, contrast-enhanced ultrasound; CT, computed-tomography; FNAC,
fine-needle aspiration cytology; LN, lymph node; MCT, mast cell tumour; SLN, sentinel lymph
node; US, ultrasound.
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proposed,1,3,4 but there is no consensus defining when and how LNs
should be assessed. Currently, the choice of the LN(s) to be sampled
relies mainly on our knowledge of anatomical lymphosomes in healthy
dogs,5 but several factors may complicate this initial approach: inter-
individual variation in the localisation and number of LNs,6,7 and alter-
ations in the lymphatic drainage pattern associated with neoplasia and
surgery.5,8 Another difficulty may be the occurrence of multiple nodal
metastases,9 and some authors have recommended the systematic
extirpation of 4 to 6 LNs for the staging of head and neck canine
tumours.10,11 With a reported 75% sensitivity of fine-needle aspira-
tion cytology (FNAC) to detect MCT nodal metastasis, LN extirpation
has also been recommended to complete MCT staging.12,13
Lymphadenectomy is an invasive procedure that often necessitates
additional surgical preparation and time, extending time under anaes-
thesia for dogs and costs for owners. It is therefore sometimes diffi-
cult to justify when the LN draining status is uncertain and/or when
the LN is particularly difficult to remove.
Sentinel lymph node (SLN) mapping techniques have been devel-
oped in human oncology to identify the first LN(s) receiving the lymph
from tumours that predominantly spread through the lymphatic sys-
tem.14 Regional lymphoscintigraphy combined with intra-operative lym-
phoscintigraphy and blue dye, the gold standard SLN mapping
technique in human oncology, has been successfully incorporated into
canine MCT staging in previous studies.15,16 Lymphoscintigraphy is
however, only available in very few veterinary centres. The use of
computed-tomography (CT) SLN mapping is mainly restricted to Japan
in human oncology,17 but is becoming a very popular technique among
veterinarians.18-22 The main advantages being the wide availability of
CT, the ability to visualize an entire area at the same time, and to per-
form 3D-reconstructions. Disadvantages are the necessity for deep
sedation or general anaesthetic, cost, risk of adverse reactions to the
iodinated contrast and its possible accumulation within the injected tis-
sues and associated LNs for a prolonged period of time,23 difficulty in
determining the ideal time to scan, and in complying with the As Low
As Reasonably Achievable radiation safety principle.19
Other SLN mapping techniques have been developed in human
oncology, including contrast-enhanced ultrasound (CEUS) or
lymphosonography, a non-ionizing and non-invasive technique.24 The
potential of this technique was validated in canine models,25-28 prior to
application in human patients diagnosed with breast cancer and cutaneous
melanoma.29-34 The main advantages are the wide availability of CEUS,
low cost, safety and rapid clearance of the contrast,35 no requirement for
general anaesthetic, quick contrast diffusion to the LNs in real-time,27 the
ability to view the fine details of the lymphatics and LNs,36 and minimal
spillover of the contrast to secondary nodes.28,37 The main disadvantages
are the need to select which lymphatic basins to scan, and inter-operator
variability. This technique seems however particularly advantageous for
dogs with MCTs as abdominal ultrasound (US) and liver/spleen US-guided
FNAC are already often performed for their staging.3,38-40
Our hypothesis was that CEUS SLN mapping could be integrated
into the routine staging of canine MCTs, from both practical and tech-
nical aspects. The primary objective was to determine the safety and
effectiveness of CEUS to identify SLNs. Secondary objectives were to
determine if the SLNs identified by CEUS coincided with the regional
LN predicted by the anatomical lymphosomes, if previous excision of
the MCT would alter CEUS SLN findings, and if CEUS uptake patterns
could identify MCT nodal metastasis.
2 | MATERIALS AND METHODS
2.1 | Case selection
All dogs included in this feasibility study were presented to the Specialist
Oncology service of the University of Edinburgh between June 2017 and
March 2019. Dogs were eligible if they were undergoing staging of a
cytologically or histologically diagnosed MCT. Dogs with scars of already
excised MCTs were also eligible, providing no regional LN was extirpated.
Owners signed an informed consent form before enrolment of their dog.
The study design, procedure protocol, and informed owner consent form
were approved by the Institutional Veterinary Ethical Review Committee.
2.2 | Study design
Clinical information was collected, including: location of the primary
MCT recorded on a body map, presence of negative prognostic fac-
tors (location, recurrence, clinical behaviour, histological grade, prolif-
eration marker, multinucleation and infiltrative pattern for
subcutaneous MCTs), size of the mass and/or scar, subjective palpa-
tion of the LNs, closest LN to the MCT and the regional LN predicted
by the anatomical lymphosomes. A standard list of lymphatic basins to
be scanned per body area was suggested and adapted to each dog
(Supplementary form 1). Dogs underwent routine procedures for stag-
ing of their MCT including serum biochemistry and haematology, tho-
racic radiographs, abdominal US, liver/spleen FNAC, and regional
LN(s) FNAC (including the regional LN predicted by the anatomical
lymphosomes, the SLN(s) identified by CEUS, and any other LNs of
interest identified by the clinician). Dogs received an intramuscular
injection of chlorpheniramine (4 mg for dogs <15 kg, 8 mg for dogs
≥15 kg) before lymphosonography, which was performed at the end
of the staging workup. Fine-needle aspiration of the identified SLN(s)
or any other LN(s) of interest identified by the clinician was performed
after lymphosonography. Dogs were checked for any potential
adverse events by a clinician immediately after lymphosonography
and at least 1 hour later and by owners thereafter. Any identified
SLNs were advised to be extirpated, but this was not necessary for
study inclusion. When it was performed, SLN(s) extirpation was
planned after lymphosonography, together with MCT resection or
scar re-excision if indicated. Information on the staging procedures
and their results, and histological characteristics of the MCTs were
collected. Cytological samples and histological sections from identified
SLNs were reviewed and classified according to previously published
standardized criteria by a board-certified clinical pathologist (P.C.) and
by a board-certified anatomical pathologist (A.M.), respectively.41,42
Prior to review, histological sections were stained with toluidine blue.
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2.3 | Lymphosonography
The contrast agent SonoVue (Bracco Imaging, Milan, Italy), based on
stabilized sulphur hexafluoride microbubbles surrounded by a phos-
pholipid shell with a mean size of 2.5 μm, was used for this study.43 A
commercially available US machine (MyLab Twice Esaote, Genova,
Italy) was used with an electric microconvex probe. In all examina-
tions, the transmission frequency ranged from 3 to 10 Mhz for
B-mode imaging, and the manufacturer's preset for contrast imaging
was used with a low mechanical index of 0.1, a frequency of 3 Mhz,
gain 50%, and a single focus on the lymph node. Images were regis-
tered as still images and video clips.
Dogs were positioned in lateral or dorsal recumbency. The rele-
vant lymphatic basins designated by an oncologist were clipped and
examined by B-mode US before injection of the contrast. Using a
25-gauge needle, 1 to 2 mL of contrast was injected peri-tumourally
with a linear threading technique from the deepest part of the tumour
to the superficial dermis, divided in four quadrants within 5 mm of the
edge of the mass or scar. Following injection, an antegrade massage
was performed for about 30 seconds, with fingers applying light strok-
ing movements over the skin from the injected site towards the LNs.
Contrast injections and antegrade massages were administered by
one oncologist (Q.F.), or by another clinician under his direction.
A timer was started after contrast injection. The lymphatic basins
were scanned according to the ordered list provided by the clinician,
and the sites of contrast injection were scanned in an attempt to fol-
low afferent lymphatic tracts. A second contrast injection was autho-
rized if no SLN was initially identified.
Only two radiologists (F.T., M.L.) performed all ultrasonographic
examinations, and all recorded images from the SLNs were retrospec-
tively blindly reviewed by a board-certified radiologist (F.T). Collected
B-mode and post-contrast sonographic features included: long and
short axis diameters, shape, architecture, nodal border characteristics,
perinodal steatitis, intranodal calcification or cystic areas, SLN detec-
tion time, afferent and efferent lymphatic tracts, enhancement and
filling patterns, and acoustic shadowing artefacts.
2.4 | Data analysis
The safety of lymphosonography was assessed based on the documen-
tation of adverse events reported by the clinicians and owners. The
effectiveness of lymphosonography was assessed by determining: the
SLN detection rate, the prevalence of nodal metastasis detected, and
any discrepancy recorded during staging (ie, distant or regional MCT
metastasis in the absence of SLN metastasis). The SLN(s) identified by
CEUS were compared with the regional LN predicted by the anatomical
lymphosomes and with the closest LN to the MCT, and were used to
build a reconstructed body map of the MCTs and their lymphatic drain-
age. The impact of previous MCT excision on lymphosonography was
assessed by determining any potential difference in SLN detection rate,
number of identified SLNs, prevalence of nodal metastasis detected,
and SLN sonographic characteristics between the MCTs that were
already excised and the ones that were not. The ability of
lymphosonography to identify MCT nodal metastasis was assessed by
determining any potential association between recorded SLN sono-
graphic characteristics and SLN histology. Enhancement patterns
recorded included: Pattern I, SLN completely homogeneously enhanced;
Pattern II, SLN partially enhanced with a disorganized architecture; Pat-
tern III, SLN not enhanced with only afferent tract(s) identified; Pattern
IV, SLN with a thin and smooth peripheral enhancing rim and hypo-
enhancing centre with a preserved architecture.
Pearson's chi-squared test and Fisher's exact test were used to
compare categorical data as appropriate. Continuous data were
evaluated for normality with the Shapiro-Wilk test. The Mann-
Whitney and Kruskal-Wallis tests were used to compare ordinal
and continuous non-normally distributed data between two or
more groups, respectively. Student's t test and One-Way Analysis
of Variance were used to compare continuous normally distributed
data between two or more groups, respectively. Statistical analyses
were performed by the free statistics software JASP (Version 0.12,
JASP Team 2020). A P-value <.05 was considered statistically sig-
nificant for all analyses.
TABLE 1 Characteristics of 59 dogs and 62 mast cell tumours
Parameter
Age (years)
Median (range) 8.8 (0.3-13.7)
Sex
Male 27 (45.8%)
Female 32 (54.2%)
Weight (kg)
Median (range) 30.45 (2.5-50.3)
Breed
Labrador 18 (30.5%)
Staffordshire terrier 4 (6.8%)
Boxer 4 (6.8%)
Golden retriever 3 (5.1%)
Weimaraner 3 (5.1%)
Other breeds (≤2) 16 (27.1%)
Cross breed 11 (18.6%)
Mast cell tumour
Subcutaneous 20 (32.3%)
Cutaneous 42 (67.7%)
Patnaik
Grade 1 3 (7.1%)
Grade 2 29 (69.1%)
Grade 3 5 (11.9%)
Unknown 5 (11.9%)
Kiupel
Low grade 29 (69.0%)
High grade 9 (21.4%)
Unknown 4 (9.6%)
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2.5 | Cell line validation statement
No cell line was used in this study.
3 | RESULTS
Fifty-nine dogs with 62 MCTs were enrolled in this study (Table 1)
and had CEUS SLN mapping integrated into their routine staging pro-
cedures (Figure 1). Two dogs had two concurrent MCTs in different
body areas, microbubble destruction naturally occurred between both
examinations by switching back to B-mode and waiting 30 minutes
before the second CEUS SLN mapping; one dog developed a second
MCT in another body area about a year following his first enrolment.
Twenty-four out of 62 (38.7%) MCTs were already resected. Median
time between previous MCT excision and CEUS SLN mapping was
27 days (range, 13-98). No adverse reaction to CEUS SLN mapping
was reported.
3.1 | SLN detection and localisation
A median of five lymphatic basins (range, 2-9) were examined per dog.
At least one SLN was identified in 59/62 MCTs (Figure 1), CEUS had
a SLN detection rate of 95.2% (95% CI: 86.5-99.0%). Seventy-four
SLNs belonging to 1 or 2 lymphatic basins were identified in 48/62
(77.4%) and 11/62 (17.8%) of MCTs, respectively (Figure 1). In four
dogs, two nodes were identified as SLNs within the same basin. No
contralateral SLN was identified. Previously excised MCTs had a sig-
nificantly lower number of SLN(s) identified (P = .034).
Palpation revealed enlargement of 7/74 (9.5%) SLNs; 18/74
(24.3%) were considered within normal limits and 49/74 (66.2%) were
non-palpable. The closest LN to the MCT was the only SLN in 31/59
(52.5%) cases, one of several SLNs in 7/59 (11.9%) cases, and not the
SLN in 35.6% (21/59) cases. By following the anatomical
lymphosomes of the MCTs, clinicians would have sampled all SLNs in
32/59 (54.2%) cases, one but not all SLNs in 6/59 (10.2%) cases, and
no SLN in 21/59 (35.6%) cases. The location of SLNs differed even
for MCTs in similar anatomic locations (Table 2). “Zones of ambiguity”
and aberrant skin lymphatic drainage were also noted (Figure 2).
3.2 | SLN pathology and clinical staging
A diagnostic cytological sample and histological sample were obtained
in 42/74 (56.7%) and 41/74 (55.4%) SLNs, respectively. Overall, a
diagnostic sample (cytology or histology) was obtained in 59/74
(79.7%) SLNs (Figure 1). No adverse event associated with FNAC was
59 dogs
31 SLNs
• SLN not found in surgery (n=10)
• SLN not extirpated because palliative care (n=12)
• SLN not extirpated because neo-adjuvant chemotherapy (n=2)
• SLN not extirpated because deemed too invasive (n=7)
Routine staging procedures
Dog enrollment
62 MCTs
CEUS SLN mapping
4 dogs
CEUS SLN mapping (n=59 dogs)
3 MCTs
No SLN identifiedSLN identified
1 SLN2 SLNs
48 MCTs11 MCTs
70 SLNs
SLN FNAC
SLN extirpation
16 SLNs
• SLN too deep / small (n=13)
• SLN extirpation planned (n=3)
FNAC not attempted
14 SLNs
FNAC non diagnostic
Diagnostic FNAC (n=40 SLNs)
20 SLNs
Histological examination (n=39 SLNs)
SLN not extirpated
11 SLNs 8 SLNs
Haematology and serum biochemistry (n=59 dogs)
Thoracic radiographs and abdominal ultrasound (n=55 dogs)
3 dogs b
1 dog a
Liver and spleen FNAC (n=56 dogs)
F IGURE 1 Flow diagram of the study. aFinancial constraints, negative prognostic factor present. bFinancial constraints, negative prognostic
factor absent. FNAC, fine-needle aspiration cytology; MCT, mast cell tumour; SLN, sentinel lymph node
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reported, whilst mild self-resolving (within 14 days) postoperative ser-
omas were noted on three occasions following extirpation of two
mandibular LNs, one mandibular and medial retropharyngeal LNs, and
one superficial inguinal LN (ipsilateral popliteal LN also extirpated).
When the original histological diagnosis was based on haematoxylin &
eosin stained sections, the agreement with the reviewed diagnosis
was only moderate (n = 29), whereas it was perfect when sections
were already stained with toluidine blue (n = 12; Supplementary form
2). Using the previously proposed cytological and histological
classification schemes,41,42 cytologically probable and certain metasta-
ses accurately identified early and overt histological metastases
(n = 6), respectively; but the other cytological classes were unable to
differentiate pre-metastasis from early metastasis in this small sample
(n = 15; Supplementary form 3).
Diagnostic cytological and/or histological samples were
obtained in 18 non-sentinel LNs, and revealed metastasis in nine of
them: five medial iliac and one axillary associated with metastatic
superficial inguinal SLNs; one superficial inguinal associated with
TABLE 2 Distribution of identified
lymphatic basin(s) for 59 mast cell
tumours
MCT localisation Lymphatic basin(s) Number of MCTs
Head/Neck (n = 10) Muzzle Mandibular 3
Forehead Mandibular 1
Parotid 1
Ear base Medial retropharyngeal 1
Pinna Superficial cervical 2
Neck (ventral) Medial retropharyngeal 1
Superficial cervical 1
Forelimb (n = 12) Shoulder Superficial cervical 4
Superficial cervical; Axillary 1
Elbow Superficial cervical 1
Axillary 1
Superficial cervical; Axillary 2
Antebrachium Superficial cervical 1
Axillary 1
Forepaw Superficial cervical 1
Trunk (n = 21) Thoracic wall Axillary 9
Axillary; Accessory axillary 1
Superficial inguinal 1
Medial iliac 1
Medial iliac; Colic 1
Back Medial iliac; Femoral 1
Abdominal wall Superficial inguinal 1
Medial iliac 1
Groin Superficial inguinal 2
Scrotum Superficial inguinal 1
Medial iliac 1
Vulva Superficial inguinal 1
Hindlimb (n = 16) Thigh Superficial inguinal 4
Stifle Superficial inguinal 1
Superficial inguinal; Medial iliac 1
Hock Popliteal 3
Superficial inguinal 2
Popliteal; Superficial inguinal 1
Popliteal; Medial iliac 2
Hindpaw Popliteal 2
Abbreviation: MCT, mast cell tumour.
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metastatic medial iliac SLN; one medial retropharyngeal associated
with metastatic ipsilateral mandibular SLN; one accessory axillary
associated with metastatic ipsilateral axillary SLN. Hepatic and/or
splenic metastasis was confirmed in three dogs with SLN metastasis,
all of which had advanced multinodal metastases including ipsi- and
contralateral superficial inguinal and medial iliac LNs. None of the
MCTs with histologically non-metastatic SLN(s) had metastasis diag-
nosed at the end of staging.
In all four MCTs that had two SLNs extirpated, histological classes
of the paired SLNs were identical (early metastasis in two MCTs, pre-
metastasis in the other two MCTs). There was no significant differ-
ence in SLN histological classes whether the MCTs had been excised
before the lymphosonography was performed or not (P = .204). The
prevalence of nodal metastasis among the 35 MCTs that had all their
SLNs extirpated was 60% (95% CI: 42.1-76.1%). The only clinical/
pathological parameter assessed that was associated with histological
nodal metastasis was the size of the primary MCT, and all five MCTs
>26 mm were metastatic (Table 3).
3.3 | SLN sonographic characteristics
The median total amount of contrast administered was 2 mL (range,
0.8-3). A contrast injection was repeated a second time in 3/5 cases in
which no SLN was initially detected, and SLN(s) were eventually identi-
fied in two of these cases. Afferent lymphatic tracts were easily identi-
fied from the injection sites but were difficult to follow all the way to
the SLN(s). The median time for SLN detection was 1 minute 40 seconds
(range, 15 seconds - 6 minutes 25 seconds). Four SLNs could not be
seen on B-mode US but became clearly visible after taking up contrast
(2 superficial inguinal, 1 accessory axillary, 1 colic). Gas artefact causing
distal acoustic shadowing was noted in 17/74 (23.0%) SLNs after injec-
tion. Efferent lymphatic tract(s) were noted in 12/74 (16.2%) SLNs.
Four main enhancement patterns were identified (Figure 3):
Pattern I, 37/74 (50%); Pattern II, 33/74 (44.6%); Pattern III, 2/74
(2.7%); Pattern IV, 2/74 (2.7%).
Pattern II included SLNs with a broad-range of contrast uptake, and
a 3-tier filling score (1 to 3) was established to further characterize it:
3, strong and diffuse filling of the SLN with only minor filling defect(s),
18/33 (54.6%); 2, moderate and obviously heterogeneous filling of the
SLN, 7/33 (21.2%); 1, minimal and mainly peripheral filling of the SLN,
8/33 (24.2%). The enhancement pattern was the only sonographic
parameter significantly associated with histological nodal metastasis
(P = .009), but splitting the enhancement pattern II with a filling score
did not help discriminate metastatic SLNs (Table 4). No difference was
noted in any of the SLN sonographic characteristics from MCT that had
or not already been excised, including enhancement patterns (P = .684).
Considering Patterns II and III as metastatic, CEUS only had a mod-
erate agreement with histology (Table 5). Performing FNAC could
increase the sensitivity of CEUS alone from 78.3% (95% CI: 56.3-92.5%)
to 94.7% (95% CI: 74-99.9%) with the combination but would not have
affected the specificity. All the metastatic LNs with a Pattern I only had
early metastasis; with the exception of one LN with overt metastasis,
which had large sheets of mast cells mostly within the sinuses and only
minor disruption of the nodal architecture.
4 | DISCUSSION
Integration of CEUS SLN mapping to MCT staging is technically feasi-
ble in routine practice. Most SLNs were clearly visible, and CEUS even
allowed the detection of small SLNs that were not visible on B-mode
US. The high SLN detection rate and high SLN positivity rate associ-
ated with this technique support its effectiveness in identifying SLNs.
Sentinel LNs enhancement patterns were associated with the meta-
static status of the nodes, but a direct clinical application is nonethe-
less limited as a result of the low sensitivity and specificity. No
adverse event was reported following lymphosonography in client-
owned dogs with MCTs, which confirms the safety of this
technique.27,29,31,32,44
The 95.2% SLN detection rate obtained in this study compares
favourably with the 60% to 96.6% and the 91.1% to 100% SLN
detection rates reported with CT lymphangiography18,19,21,45 and
1
2
3
4
5
6
7
8
9
10
11
F IGURE 2 Reconstructed body map of 59 canine mast cell
tumours and their associated lymphatic drainage. Lymph nodes (LNs):
1, mandibular LNs (turquoise); 2, parotid LNs (yellow); 3, superficial
cervical LNs (orange); 4, axillary LNs (green); 5, medial iliac LNs (blue);
6, superficial inguinal LNs (yellow); 7, popliteal LNs (red); 8, medial
retropharyngeal LNs (mauve); 9, colic LNs (purple); 10, femoral LNs
(pink); 11, accessory axillary LNs (ruby). Masses and scars have the
colours of their identified sentinel LNs (SLNs); lymphosomes of the
expected LNs are represented in colour; efferent lymphatic vessels
are represented from the mandibular and parotid LNs to the medial
retropharyngeal LNs, and from the popliteal and superficial inguinal
LNs to the medial iliac LNs. “Zones of ambiguity” of lymphatic
drainage are noted on the forelimb between superficial cervical and
axillary LNs; the trunk between axillary, superficial inguinal and medial
iliac LNs; and the hindlimb between superficial inguinal, medial iliac
and popliteal LNs. Medial retropharyngeal, colic, femoral and medial
iliac LNs were identified as aberrant SLNs in 5 MCTs (aberrant
lymphatics in doted lines). The accessory axillary LN was identified as
an interval node to the axillary LN in 1 MCT. Note that it cannot be
ruled out the medial iliac LN was a false-positive second order LN
from popliteal and superficial inguinal SLNs in 2 and 1 MCTs,
respectively
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lymphoscintigraphy/intraoperative methylene blue techniques,15,16
respectively. In humans, lymphosonography also identifies at least
one SLN in 89% to 97% of patients, which is not different from the
traditional techniques.30,32-34 An average of 1.2 (74/62) SLNs per
MCT was identified using CEUS, whereas an average of 1.6 (88/54)
SLNs per MCT was identified with lymphoscintigraphy/
intraoperative methylene blue, when compiling the cases from two
studies.15,16 It is difficult to compare these figures, but it is possible
that the dual-labelled technique truly identifies a higher number of
LNs. Indeed, radiopharmaceuticals and blue dyes are associated
with significant spill-over resulting in the identification of non-
sentinel LNs.32,46-48 In a human study, CEUS identified less LNs
than the dual-labelled technique, but the metastatic rate was higher
among the LNs identified by CEUS, supporting that CEUS may
identify the SLNs more accurately.33 Significant spill-over has also
been confirmed with iodinated contrast in one study investigating
CT lymphangiography in dogs, since second and third order LNs
were commonly identified.19 It is assumed that the large particle
size of the contrast agent used with lymphosonography prevents
its uptake by second order LNs. In addition, it has also been noted
that the nodal macrophages can trap (phagocytose) the contrast
agent.27,37,49 Nonetheless, efferent lymphatic tracts were detected
in a recent study50 and in this one, making the detection of second
order LNs also possible with CEUS.
Based on the results from this CEUS study, performing SLN map-
ping is necessary to correctly identify draining LNs, since clinicians
would have correctly identified all SLNs in only 54.2% MCTs. This
may be partly explained by so-called “zones of ambiguity”.46 Aberrant
TABLE 3 Characteristics of 35 mast cell tumours with sentinel lymph node histology
Histological classification42 Histological nodal status
MCT
parameter
Non-
metastatic
HN0 (n = 4)
Pre-metastatic
HN1 (n = 10)
Early metastasis
HN2 (n = 15)
Overt
metastasis
HN3 (n = 6)
Non-metastatic
HN0/HN1 (n = 14)
Metastatic
HN2/HN3
(n = 21) P-value
Skin location 1.0
Cutaneous
(n = 20)
2 6 8 4 8/20 (40%) 12/20 (60%)
Subcutaneous
(n = 15)
2 4 7 2 6/15 (40%) 9/15 (60%)
Patnaïk Grade 1.0
Grade 1
(n = 2)
0 1 1 0 1/2 (50%) 1/2 (50%)
Grade 2
(n = 16)
2 4 7 3 6/16 (37.5%) 10/16 (62.5%)
Grade 3
(n = 2)
0 1 0 1 1/2 (50%) 1/2 (50%)
Kiupel Grade 1.0
Low grade
(n = 16)
2 4 7 3 6/16 (37.5%) 10/16 (62.5%)
High grade
(n = 4)
0 2 1 1 2/4 (50%) 2/4 (50%)
Mitotic counta .132
Median
(range)
1.5 (1–2) 1 (0–8) 1 (0-35) 1 (1–10) 1 (0–8) 1 (0–35)
Tumour size
(mm)
.039
Median
(range)
10 (8-26) 11.5 (2-25) 17 (3-42) 23(18-50) 10 (2-26) 20 (3-50)
Negative
prognostic
factorb
.204
Median
(range)
0 (0–1) 0.5 (0-3) 1 (0-2) 1 (0-3) 0 (0-3) 1 (0-3)
aNumber of mitotic figures per 10 high-power fields.
bLocation (eg, scrotum, muzzle), recurrence, clinical behaviour (eg, ulceration, rapid growth), histological grade (high grade Patnaïk and/or Kiupel), prolifera-
tion marker (eg, mitotic count >5 for cutaneous and >4 for subcutaneous MCTs, Ki67 index >1.80% laboratory cut-off), multinucleation and infiltrative pat-
tern for subcutaneous MCTs.
Abbreviation: MCT, mast cell tumour.
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lymphatic drainage was also noted with the medial retropharyngeal
and colic LNs not expected to drain the skin, and the medial iliac and
femoral LNs not expected to drain the skin of the scrotum and the
rump, respectively.7 Aberrant lymphatic drainage and the identifica-
tion of unexpected SLNs is also a well-known phenomenon in human
cancers.51,52 The most striking example was a MCT on the caudo-
dorsal thoracic wall, which had colic and medial iliac SLNs identified.
Remarkably, after completion of this feasibility study, another of our
canine patients with a large MCT on the thigh also had a colic SLN
identified. We also report an accessory axillary SLN as an interval
node to the axillary SLN. Both axillary and accessory axillary nodes
had histological early metastasis, which highlights the importance of
identifying interval nodes even if they probably occur less frequently
in dogs than in human.53
The prevalence of histological nodal metastasis in dogs with
MCTs was 60%, which is similar to what was previously reported
using regional lymphoscintigraphy combined with intra-operative lym-
phoscintigraphy and blue dye.15,16 It is however higher than the 42%
previously reported in our institution when SLN mapping was not part
of the routine staging,12 and the 45.9% reported in another study.13
This supports the effectiveness of CEUS SLN mapping; but unlike in
these two retrospective studies, in this current study all histological
sections were stained with toluidine blue, which may also have
affected these results.
Remarkably, the prevalence of nodal metastasis for subcutaneous
MCTs was 60%, whilst it was previously reported to be only 4%.54
The prevalence of nodal metastasis for cutaneous MCTs was also
higher in our study compared with another large retrospective
study,55 in particular for Patnaik grade 2 MCTs (16.2% in previous
publication55 and 62.5% in this study). It is difficult to draw any con-
clusion on the impact of SLN mapping from this, since the numbers in
this feasibility study were small and the quality of LN assessment was
variable in these retrospective studies. Nonetheless, this highlights
the marked difference in the reported prevalence of nodal metastasis
depending on the regional LN(s) staging procedures performed. Fol-
lowing the use of CEUS SLN mapping and standard histological
assessment, none of the grading systems nor any other prognostic
factors assessed were significantly associated with nodal metastasis.
Only the size of the primary tumour was associated with LN metasta-
sis, but tumours as small as 3 mm could still be metastatic. In two pre-
vious studies using SLN mapping15 and standard histological
assessment,13 the presence of recognized prognostic factors did not
correlate with nodal metastasis either. Although this feasibility study
is not adequately powered to analyse the association between prog-
nostic factors and nodal metastasis, these results suggest extirpation
of SLN(s) may be required in all MCTs to achieve an accurate clinical
staging. Future studies are needed to confirm these findings and
determine if this procedure would also be accompanied with an
improved outcome.
In this study, there was no significant difference in SLN histological
and sonographic characteristics whether the MCTs had been excised
before the lymphosonography was performed or not. Sentinel LN
biopsy after previous wide local excision of cutaneous melanomas in
humans also seems to accurately identify nodal metastases.56 MCTs
that had already been excised had however significantly fewer SLNs
identified, which could be explained by the surgical disruption of the
natural lymphatic drainage.57 If this finding is true, then performing
wide local excision of the primary tumour before SLN mapping may
carry the risk of leaving an undetected metastatic SLN, which could in
turn alter the outcome of the dog, since extirpation of metastatic LNs
likely has a therapeutic benefit.58-60 This should be further investigated
as it may have resulted from a selection bias or from a type I error.
F IGURE 3 Sentinel lymph node enhancement patterns observed with contrast-enhancement ultrasound. Four main enhancement patterns
were identified: Pattern I, SLN completely and homogeneously enhanced, A; Pattern II, SLN partially enhanced with a disorganized architecture
(D, E, F); Pattern III, SLN not enhanced with only afferent tract(s) identified, B; Pattern IV, SLN with a thin and smooth peripheral enhancing rim
and hypoenhancing centre with a preserved architecture, C. Pattern II was further stratified into a 3-tier filling score: 3, strong and diffuse filling
of the SLN with only minor filling defect(s) (D); 2, moderate and obviously heterogeneous filling of the SLN (E); 1, minimal and mainly peripheral
filling of the SLN, F. For each subfigure, the B-mode image is on the left side, with the corresponding CEUS image on the right side. CEUS,
contrast-enhanced ultrasound; SLN, sentinel lymph node
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Three of the four enhancement patterns described in this study
(Patterns I, II and III) were previously proposed in breast cancer CEUS
SLN mapping.33,61 We also reported an additional pattern with a thin
and smooth peripheral enhancing rim (Pattern IV) which was noted in
two SLNs. This was evocative of a particular type of lymph node
structure, when the lymphatic vessel runs over the surface of the LN
without discharging its content, which is one of the explanations pro-
posed for false-negative SLNs and skip metastasis.62 This remains
speculative, however, and this pattern would need to be reported in
other studies before its relevance can be confirmed.
This feasibility study had several limitations. First, SLNs iden-
tified by CEUS were generally not marked, and it is therefore diffi-
cult to confirm the LNs extirpated were the ones identified by
CEUS. This is the disadvantage of preoperative techniques, which
could be overcome by deployment of a guidewire for instance.32
It could also be possible to inject SLNs preoperatively with blue
dye, or to combine CEUS with intraoperative blue dye SLN map-
ping. The systematic combination of CEUS with a blue dye tech-
nique could also allow a better visualization of the SLNs to
extirpate, as 10 SLNs could not be found in surgery in this study.
Second, although we made every effort to be consistent in the
selection of the lymphatic basins assessed by CEUS, this proce-
dure remains difficult to standardize, and this may have affected
the results of this study. Third, CEUS was not directly compared
with other SLN mapping techniques such as lymphoscintigraphy
or blue dye injection.15 Fourth, SLN enhancement Pattern III may
be subtle and might have been missed in a few markedly enlarged
LNs identified as non-sentinel. This should be more carefully
examined in future studies. Fifth, it is difficult to rule out that
some medial iliac SLNs may have been second order LNs to popli-
teal and superficial inguinal SLNs. Sixth, not all SLNs were histo-
logically assessed.
5 | CONCLUSION
CEUS SLN mapping is safe and associated with a high SLN detec-
tion rate. Given the absence of discrepancy with the rest of clinical
staging and the high positive LN rate, this technique seems to accu-
rately predict the metastatic status of dogs with MCTs. Draining
LNs are difficult to correctly identify, and SLN mapping should be
recommended before sampling LNs in dogs with MCTs. Excising
MCTs before CEUS SLN may alter the results. Enhancement pat-
terns only had a moderate agreement with SLN histological meta-
static status. Integration of CEUS SLN mapping into the routine
staging of MCTs is promising, but future studies are required to
refine this procedure and to investigate if it would translate into a
clinical benefit.
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